Atenolol + olmesartan medoxomil
ApprovedTerminated 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Essential Hypertension
Conditions
Essential Hypertension, Carotid Plaque
Trial Timeline
May 1, 2010 → Jun 1, 2011
NCT ID
NCT01132768About Atenolol + olmesartan medoxomil
Atenolol + olmesartan medoxomil is a approved stage product being developed by Daiichi Sankyo for Essential Hypertension. The current trial status is terminated. This product is registered under clinical trial identifier NCT01132768. Target conditions include Essential Hypertension, Carotid Plaque.
What happened to similar drugs?
14 of 20 similar drugs in Essential Hypertension were approved
Approved (14) Terminated (1) Active (6)
✅Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg + Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mgYuhanApproved
✅olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessaryDaiichi SankyoApproved
✅olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessaryDaiichi SankyoApproved
Hype Score Breakdown
Clinical
20
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01132768 | Approved | Terminated |
Competing Products
20 competing products in Essential Hypertension